Literature DB >> 22057699

Can we really use ß-lactam/ß-lactam inhibitor combinations for the treatment of infections caused by extended-spectrum ß-lactamase-producing bacteria?

Federico Perez, Robert A Bonomo.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22057699     DOI： 10.1093/cid/cir793

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


× No keyword cloud information.
  21 in total

1.  10 x '20 Progress--development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of America.

Authors:  Helen W Boucher; George H Talbot; Daniel K Benjamin; John Bradley; Robert J Guidos; Ronald N Jones; Barbara E Murray; Robert A Bonomo; David Gilbert
Journal:  Clin Infect Dis       Date:  2013-04-17       Impact factor: 9.079

2.  Determining the optimal ceftriaxone MIC for triggering extended-spectrum β-lactamase confirmatory testing.

Authors:  Yanjie Huang; Karen C Carroll; Sara E Cosgrove; Pranita D Tamma
Journal:  J Clin Microbiol       Date:  2014-04-16       Impact factor: 5.948

3.  Carbapenem therapy is associated with improved survival compared with piperacillin-tazobactam for patients with extended-spectrum β-lactamase bacteremia.

Authors:  Pranita D Tamma; Jennifer H Han; Clare Rock; Anthony D Harris; Ebbing Lautenbach; Alice J Hsu; Edina Avdic; Sara E Cosgrove
Journal:  Clin Infect Dis       Date:  2015-01-13       Impact factor: 9.079

4.  Risk Factors for and Outcomes of Bacteremia Caused by Extended-Spectrum ß-Lactamase-Producing Escherichia coli and Klebsiella Species at a Canadian Tertiary Care Hospital.

Authors:  My-Linh Nguyen; Baldwin Toye; Salmaan Kanji; Rosemary Zvonar
Journal:  Can J Hosp Pharm       Date:  2015 Mar-Apr

Review 5.  Treatment of Infections Caused by Extended-Spectrum-Beta-Lactamase-, AmpC-, and Carbapenemase-Producing Enterobacteriaceae.

Authors:  Jesús Rodríguez-Baño; Belén Gutiérrez-Gutiérrez; Isabel Machuca; Alvaro Pascual
Journal:  Clin Microbiol Rev       Date:  2018-02-14       Impact factor: 26.132

6.  Activity of Ceftolozane-Tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae Isolates Collected from Respiratory Tract Specimens of Hospitalized Patients in the United States during 2013 to 2015.

Authors:  Mariana Castanheira; Leonard R Duncan; Rodrigo E Mendes; Helio S Sader; Dee Shortridge
Journal:  Antimicrob Agents Chemother       Date:  2018-02-23       Impact factor: 5.191

7.  Mutations in blaKPC-3 That Confer Ceftazidime-Avibactam Resistance Encode Novel KPC-3 Variants That Function as Extended-Spectrum β-Lactamases.

Authors:  Ghady Haidar; Cornelius J Clancy; Ryan K Shields; Binghua Hao; Shaoji Cheng; M Hong Nguyen
Journal:  Antimicrob Agents Chemother       Date:  2017-04-24       Impact factor: 5.191

8.  Appropriateness of empirical treatment and outcome in bacteremia caused by extended-spectrum-β-lactamase-producing bacteria.

Authors:  Florine N J Frakking; Wouter C Rottier; J Wendelien Dorigo-Zetsma; Jarne M van Hattem; Babette C van Hees; Jan A J W Kluytmans; Suzanne P M Lutgens; Jan M Prins; Steven F T Thijsen; Annelies Verbon; Bart J M Vlaminckx; James W Cohen Stuart; Maurine A Leverstein-van Hall; Marc J M Bonten
Journal:  Antimicrob Agents Chemother       Date:  2013-04-22       Impact factor: 5.191

Review 9.  Bacterial sepsis : Diagnostics and calculated antibiotic therapy.

Authors:  D C Richter; A Heininger; T Brenner; M Hochreiter; M Bernhard; J Briegel; S Dubler; B Grabein; A Hecker; W A Kruger; K Mayer; M W Pletz; D Storzinger; N Pinder; T Hoppe-Tichy; S Weiterer; S Zimmermann; A Brinkmann; M A Weigand; C Lichtenstern
Journal:  Anaesthesist       Date:  2019-02       Impact factor: 1.041

Review 10.  [Bacterial sepsis : Diagnostics and calculated antibiotic therapy].

Authors:  D C Richter; A Heininger; T Brenner; M Hochreiter; M Bernhard; J Briegel; S Dubler; B Grabein; A Hecker; W A Krüger; K Mayer; M W Pletz; D Störzinger; N Pinder; T Hoppe-Tichy; S Weiterer; S Zimmermann; A Brinkmann; M A Weigand; Christoph Lichtenstern
Journal:  Anaesthesist       Date:  2017-10       Impact factor: 1.041
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.